Quick Takeaways
- VANGUARD GROUP INC filed SCHEDULE 13G for Avalo Therapeutics Inc Common Stock (AVTX).
- Disclosed ownership: 5.3%.
- Date of event: 30 Sep 2025.
VANGUARD GROUP INC - 30 Sep 2025 SCHEDULE 13G Report for Avalo Therapeutics Inc Common Stock (AVTX)
- Filing Manager
- VANGUARD GROUP INC
- Reporting Manager
- The Vanguard Group
- Security
- Avalo Therapeutics Inc Common Stock
- Symbol
- AVTX
- Shares outstanding
- 13,168,004 shares
- Disclosed Ownership
- 692,637 shares
- Ownership
- 5.3%
- Form type
- SCHEDULE 13G
- Filing time
- 30 Oct 2025, 14:04:47 UTC
- Date of event
- 30 Sep 2025
- Next filing
- 30 Jan 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"VANGUARD GROUP INC disclosed 5.3% ownership in Avalo Therapeutics Inc Common Stock (AVTX) on 30 Sep 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 30 Oct 2025, 14:04.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| The Vanguard Group | 5.3% | 692,637 | 0 | 55,800 | Ashley Grim | Head of Global Fund Administration |